AMD3100 octahydrochloride hydrate, >=97% (NMR), solid

Code: a5602-5mg D2-231

Not available outside of the UK & Ireland.

Application

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcin...


read more

Your Price
$155.32 5MG
REQUEST

Not available outside of the UK & Ireland.

Application

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases.

Biochem/physiol Actions

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5 mg in glass bottle

assay≥97% (NMR)
formsolid
InChI keyGKFHDCZYJHUPEN-UHFFFAOYSA-N
InChI1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2
originatorSanofi Aventis
Quality Level100
SMILES stringCl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2
solubilityH2O: ≥10 mg/mL, clear
storage conditiondesiccated
storage temp.−20°C
Cas Number155148-31-5
This product has met the following criteria: